The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Ipca Laboratories Ltd

Ipca Laboratories Ltd

BSE 524494 · NSE IPCALAB · ISIN INE571A01038 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹1,958.65

+0.35%

BSE close, 28 August 2026

Market cap

₹49,682.96 cr

25.4 cr shares · Mid cap

Free float

₹27,130.18 cr

as published

P/E · P/B

40.0× · 7.37×

EPS ₹49.02 · BV ₹265.76

FY25-26 rev / PAT

7,336.75 / 1,132.52

₹ cr, as filed

Filings, window

10

2 selected · 20%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹1,252.95 52-WK HIGH ₹1,990.05 ₹1,958.65 96% of range
Against 52-week high-1.6%
Against 52-week low+56.3%
Day change+0.35%
Size bandMid cap
Index membershipNIFTY 500

Valuation as published by BSE

Earnings per share₹49.02
Price / earnings39.96×
Price / book7.37×
Book value — derived, price ÷ P/B₹265.76
Return on equity18.46%
Operating margin28.08%
Net margin17.61%

Consistency check

P/B ÷ P/E, which must equal ROE
18.44%
ROE as published
18.46%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 2,119.24 373.29 14.71 28.08% 17.61%
Mar-26 · Q 1,814.35 262.29 10.34 23.74% 14.46%
FY25-26 7,336.75 1,132.52 44.64 25.14% 15.44%

Quarter on quarter

Revenue, quarter on quarter
+16.8%
Net profit, quarter on quarter
+42.3%
Operating margin, quarter on quarter
+434 bps

Disclosure profile 10 filings in the window

0 median 17.0 p75 · 25 sector max 52 10 16th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Board Outcome1
Results1
Selected sub-total2
Procedural
Analyst / Investor Meet3
AGM / EGM2
Board Meeting1
Newspaper Publication1
Trading Window1
Procedural sub-total8
Total10

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

10 filings · 2 selected · busiest 2026-08-13 and 2026-08-14

Filing rhythm · the twelve most recent

2026-07-282026-09-22

SelectedProcedural

Filings

10 in the window · 15 earlier on record

  1. 22 September 2026 ·

    Trading Window

    Closure of Trading Window

    Closure of Trading Window

    Insider Trading / SAST / Closure of Trading Window View filing →

  2. 17 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Transcript of Conference Call

    Company Update / Analyst / Investor Meet View filing →

  3. 14 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Audiolink for Conference Call held on 14.08.2026

    Company Update / Analyst / Investor Meet View filing →

  4. 14 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Copy of Newspaper Publication

    Company Update / Newspaper Publication View filing →

  5. 14 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    76th AGM - Voting Results and Scrutinizer Report

    AGM/EGM / AGM View filing →

  6. 13 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of AGM

    AGM/EGM / AGM View filing →

  7. 13 August 2026 ·

    Results

    Standalone And Consolidated Unaudited Financial Results For Q1FY27

    Standalone and Consolidated Unaudited Financial Results for Q1FY27

    Result / Financial Results View filing →

  8. 13 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results For Q1FY27

    Standalone and Consolidated Unaudited Financial Results for Q1FY27

    Board Meeting / Outcome of Board Meeting View filing →

  9. 6 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Conference Call to discuss Q1FY27 Results

    Company Update / Analyst / Investor Meet View filing →

  10. 28 July 2026 ·

    Board Meeting

    Board Meeting Intimation for Standalone And Consolidated Financial Results For 1St Quarter Ended 30Th June, 2026

    Ipca Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....

    Board Meeting / Board Meeting View filing →

RSS feed for Ipca Laboratories Ltd · the 50 most recent filings